Hoechst Pakistan Limited

HPL

PK0021801011

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1,230 ^PKR	-.--%		-11.99%	+2.50%

Mar. 18	Hoechst Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Hoechst Pakistan Limited Announces Company Secretary Changes	CI

Hoechst Pakistan : NOTICE OF ANNUAL GENERAL MEETING (PRE-PUBLICATION)

March 15, 2024 at 03:42 am EDT

Ref: Fin-0005/2024

March 15, 2024

The General Manager

Pakistan Stock Exchange Limited

Stock Exchange Building

Stock Exchange Road

Karachi -74000.

SUBJECT: NOTICE OF ANNUAL GENERAL MEETING (PRE-PUBLICATION)

Dear Sir

In accordance with Clause 5.6.9 (b) of the PSX Rule Book, please find enclosed herewith a copy of captioned notice to the shareholders of Hoechst Pakistan Limited (formerly Sanofi-Aventis Pakistan Limited), prior to its publication in newspapers.

The appended notice will be published in newspapers namely Business Recorder [English] and Nawa-i- Waqt [Urdu] on Monday, March 18, 2024.

Yours sincerely

Syed Muhammad Taha Naqvi

Company Secretary

Encl: As above.

Attachments

Original Link
Original Document
Permalink

Disclaimer

Hoechst Pakistan Ltd. published this content on 15 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 March 2024 07:41:02 UTC.

Latest news about Hoechst Pakistan Limited

Hoechst Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 17	CI
Hoechst Pakistan Limited Announces Company Secretary Changes	Nov. 01	CI
Hoechst Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Oct. 31	CI
Sanofi-aventis Pakistan Limited will Change its Name to Hoechst Pakistan Limited	23-09-05	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Sanofi-aventis Pakistan Limited Announces CEO Changes	23-06-13	CI
Sanofi-aventis Pakistan Limited Announces Retirement of Dr. Asim Jamal as Managing Director, Effective June 30, 2023	23-06-13	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-02	CI
Sanofi Aventis Pakistan Limited Announces Change of Directors	23-05-01	CI
The Investor Consortium comprised of Packages Limited, IGI Investments Limited and Ali Gohar & Co. Ltd completed the acquisition of 52.87% stake in sanofi-aventis Pakistan Limited from Sanofi Foreign Participations B.V.	23-04-27	CI
Pakistan defers decision on drug price rise as pharma firms struggle	23-03-27	RE
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-29	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-31	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-27	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-28	CI
Sanofi-Aventis Pakistan Limited Recommends Final Cash Dividend for the Year Ended December 31, 2020	21-03-02	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-02	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-10-27	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2020	20-04-29	CI
Sanofi-Aventis Pakistan Limited Recommends Final Cash Dividend for the Year Ended December 31, 2019	20-03-03	CI
Sanofi-Aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-03	CI
Sanofi Aventis Pakistan Limited Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-10-28	CI

Chart Hoechst Pakistan Limited

Duration

Period

More charts

Company Profile

Hoechst Pakistan Limited, formerly Sanofi Aventis Pakistan Limited, is a pharmaceutical company, which is engaged in the manufacturing and selling of pharmaceutical and consumer products. It offers medicines, consumer healthcare products, generics and animal health products. Its products for diabetes include Amaryl, Amaryl MSR, Daonil, Neodipar, Toujeo, Lantus, SoloSTAR and Apidra. Its oncology products include Thyrogen, Jevtana, Taxotere, Eloxatin and Fludara. Its nephrology product is Renvela. Its organ transplantation is Thymoglobuline. Its urology product is Xatral. Its pain management products are No-Spa and Muscoril. Its antiemetic product includes Stemetil. Its allergy management product includes Telfast, Telfast-D, Avil, Nasacort, Phenergan and Tixylix. Its sleep disorder product is Stilnox. Its other products include Haemaccel, Plavix, CoPlavix, Aprovel, CoAprovel, Cordarone, Clexane, Tritace, CoTritace, Winstor, Lasix, Flagyl, Tarivid, Claforan, Aventriax, Orelox, and others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HOECHST PAKISTAN LIMITED	+2.50%	42.61M
ELI LILLY AND COMPANY	+34.00%	704B
NOVO NORDISK A/S	+26.77%	577B
JOHNSON & JOHNSON	-7.75%	348B
MERCK & CO., INC.	+18.53%	327B
ABBVIE INC.	+4.95%	288B
ASTRAZENECA PLC	+14.85%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-4.89%	147B